Optimization of NULOJIX (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Belatacept (Primary) ; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
- Indications Kidney-pancreas transplant rejection
- Focus Biomarker; Therapeutic Use
- 15 Sep 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 15 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Aug 2016, as reported by ClinicalTrials.gov.
- 22 Feb 2013 New trial record